Blog
RSS FeedPosted by Michael Wonder on 19 Oct 2023
Health economic assessment of Spinraza for type 5q spinal muscular atrophy
18 October 2023 - TLV has produced a health economic knowledge base for the regions for Spinraza (nusinersen sodium) for the ...
Posted by Michael Wonder on 21 Jun 2023
Imbruvica is included in the high-cost protection with a changed benefit limitation
19 June 2023 - Ibrutinib (Imbruvica)140 mg, 280 mg & 420 mg tablets are now subsidised for the treatment ...
Posted by Michael Wonder on 16 Feb 2023
Health economic assessment of Kimmtrak in disseminated ocular melanoma
16 February 2023 - The assessment applies to Kimmtrak as the sole treatment for adult patients with melanoma in the ...
Posted by Michael Wonder on 20 Jun 2022
Zeposia is included in the high-cost protection with limitation
17 June 2022 - Zeposia (ozanimod) is included in the high-cost protection with limited subsidy from 17 June 2022. ...
Posted by Michael Wonder on 20 Jun 2022
Givlaari is included in the high-cost protection with limitation
17 June 2022 - Givlaari (givosiran) is included in the high-cost protection with limited subsidy to reduce attacks in patients with ...
Posted by Michael Wonder on 17 May 2022
Health economic assessment of Xevudy for the treatment of COVID-19
17 May 2022 - TLV has produced a health economic assessment for the regions for the drug Xevudy (sotrovimab). ...
Posted by Michael Wonder on 07 Feb 2022
Health economic assessment of Opdivo in cancer of the oesophagus or upper gastro-intestinal tract
7 February 2022 - TLV has produced a health economic assessment for the regions for Opdivo (nivolumab). ...
Posted by Michael Wonder on 27 Jan 2022
The price of cystic fibrosis drugs is still too high
27 January 2022 - The Swedish Dental and Pharmaceutical Benefits Agency, TLV, has decided that Kaftrio and Kalydeco for cystic fibrosis ...
Posted by Michael Wonder on 15 Jul 2021
Health economic assessment of Oncotype DX in breast cancer
12 July 2021 - At the request of the regions' medical technology product council, the MTP council, TLV has carried out ...
Posted by Michael Wonder on 21 Apr 2021
Additional analysis of Luxturna in the treatment of visual impairment caused by hereditary eye disease
21 April 2021 - TLV has made a supplementary analysis to the previous evaluation of Luxturna, as Novartis has submitted new ...
Posted by Michael Wonder on 25 Mar 2021
Too high price for drugs for cystic fibrosis
25 March 2021 - The Swedish Dental and Pharmaceutical Benefits Agency, TLV, says no to subsidising the drugs Kaftrio and Kalydeco ...
Posted by Michael Wonder on 07 Dec 2020
Health economic assessment of Beovu in wet age-related macular degeneration
4 December 2020 - TLV has produced a health economic assessment for the regions for Beovu (brolucizumab). ...
Posted by Michael Wonder on 26 Nov 2020
Takhzyro is not included in the high-cost protection
26 November 2020 - Takhzyro (lanadelumab) is a subcutaneous injection intended for routine prevention of recurrent hereditary seizures, angioedema in patients ...
Posted by Michael Wonder on 30 Sep 2020
Saxenda is not included in the high-cost protection
29 September 2020 - Liraglutide (Saxenda), which is intended for weight control in adult patients with obesity or are overweight, ...
Posted by Michael Wonder on 06 Sep 2020
Venclyxto in combination with obinutuzumab is included in the high-cost protection with limitation
28 August 2020 - Venclyxto (venetoclax) is already included in the high-cost protection with limited subsidy. ...